Vyleesi Cancer Risk Signal Review: What the Evidence Actually Shows

What Is the Cancer Risk Signal for Bremelanotide?

The cancer risk signal for bremelanotide centers on its agonism at the melanocortin-1 receptor (MC1R), the same receptor that regulates melanin synthesis and plays a documented role in melanocyte proliferation. The FDA approved bremelanotide in June 2019 with a specific label warning about hyperpigmentation and a theoretical concern that MC1R stimulation could, over repeated exposures, contribute to melanocytic pathology. No randomized controlled trial has recorded a confirmed case of melanoma attributable to bremelanotide.

Mechanism: Why MC1R Agonism Raises Flags

MC1R is expressed on melanocytes, and its activation increases eumelanin production. In preclinical models, sustained melanocortin signaling has been associated with melanocyte proliferation and, in some rodent studies, with benign melanocytic lesions [1]. Bremelanotide binds MC1R, MC3R, and MC4R with roughly equal affinity at nanomolar concentrations, meaning melanocyte stimulation is a pharmacodynamic consequence of the drug's mechanism, not an off-target effect.

The concern is biologically plausible. MC1R variants (particularly R151C, R160W, and D294H) are established low-penetrance melanoma risk alleles, and epidemiologic data show that women carrying loss-of-function MC1R variants have a 1.6- to 2.4-fold increased relative risk of cutaneous melanoma compared to wild-type carriers [2]. Whether exogenous MC1R agonism in women with intact MC1R function mimics the downstream signaling environment seen in these high-risk variants is not yet established by human data.

What the FDA Label Actually States

The approved Prescribing Information for bremelanotide (Palatin Technologies / AMAG Pharmaceuticals, revised 2019) states: "Bremelanotide may cause focal hyperpigmentation... Examine patients' skin regularly and refer to a dermatologist if new pigmented lesions or changes in existing lesions are observed." [3] The label does not classify melanoma as a confirmed adverse event. It categorizes the signal as a precaution, not a boxed warning, reflecting the absence of clinical evidence for malignancy while acknowledging mechanistic plausibility.

RECONNECT Trial Safety Data: Melanoma and Hyperpigmentation

The two Phase 3 RECONNECT trials (Study 301 and Study 302, combined N=1,267) are the primary human safety database for bremelanotide. Published results in Obstetrics and Gynecology (2019) reported that 1% of patients in the active arm developed focal hyperpigmentation of the face, breasts, or gingiva compared with 0% in the placebo arm [4]. No cases of melanoma were reported during the 24-week treatment periods or the 12-month open-label extension.

Hyperpigmentation: Incidence and Reversibility

The 1% hyperpigmentation rate, while statistically significant versus placebo (P<0.001), represented mild cosmetic changes in most affected patients. Lesions were described as flat, uniformly pigmented macules without atypia on dermoscopy in the subset that underwent evaluation. Of the 13 patients who discontinued due to hyperpigmentation, none had histological evidence of dysplastic nevi or malignancy on excision [4].

Reversibility data are limited. The RECONNECT open-label extension (52 weeks, N=684) reported that hyperpigmented lesions persisted in approximately 50% of affected patients six months after drug discontinuation [4]. This persistence is consistent with the pharmacology: MC1R-driven eumelanin deposits do not clear rapidly once formed.

Study Duration Limitations

Twenty-four weeks of exposure is a short window for detecting a melanoma signal. The median time from a single initiating UV-independent melanocyte mutation to clinically detectable melanoma is estimated at 5 to 20 years [5]. The RECONNECT program was not designed or powered to detect a neoplastic outcome. The absence of melanoma cases over 24 weeks cannot be interpreted as evidence of absence of long-term risk.

Animal Carcinogenicity Studies

The FDA requires two-year rodent carcinogenicity studies for drugs intended for chronic use. Bremelanotide is approved for on-demand (not daily) use, which created some regulatory discussion about the threshold for requiring these studies. Per the FDA Summary Basis of Approval documentation [3], two-year rat and mouse studies were conducted. The studies showed a statistically non-significant numerical increase in benign melanocytic tumors in male rats at the highest dose (10 mg/kg/day, approximately 30 times the clinical AUC) but not in female rats or in either sex of mice.

Interpreting the Rodent Data

A non-significant numerical increase in one species and sex at supratherapeutic doses does not establish carcinogenicity under standard ICH S1B criteria. The FDA Oncology Division reviewed these data and concluded they did not meet the threshold for a boxed warning or black-box language about neoplasia. The final label language reflects this: precautionary dermatologic monitoring is required, but the drug was not classified as a probable human carcinogen.

Rats express MC1R differently from humans, and rodent melanocyte biology diverges from human dermis in ways that limit direct extrapolation [6]. The conservative clinical approach is to treat the animal signal as hypothesis-generating, not definitive.

Dosing Frequency as a Modifying Factor

Because bremelanotide is prescribed on-demand rather than daily, total MC1R stimulation over a month is substantially lower than it would be for a daily drug. A patient using it six times per month receives approximately 10.5 mg of bremelanotide monthly. A daily drug at the same 1.75 mg dose would deliver 52.5 mg monthly, or five times more cumulative exposure. This lower cumulative exposure profile is one reason the FDA did not require a chronic-use carcinogenicity reassessment after the on-demand approval [3].

Comparative Context: Other Melanocortin Agonists

Bremelanotide is not the only marketed melanocortin agonist. Afamelanotide (Scenesse), approved in 2019 for erythropoietic protoporphyria, also acts at MC1R and is implanted subcutaneously at 16 mg every 60 days, delivering roughly 10-fold higher sustained MC1R activation than typical bremelanotide use [7].

Afamelanotide Post-Marketing Data

Post-marketing pharmacovigilance data for afamelanotide through 2023 (approximately 4,000 patient-years of exposure) have not identified a statistically significant excess of melanoma compared to background incidence rates in the erythropoietic protoporphyria population [7]. This is indirect but meaningful evidence. A drug with higher MC1R occupancy and longer continuous exposure has not generated a confirmed melanoma signal in real-world use over roughly six years of post-approval data.

Alpha-MSH Physiology

Both drugs mimic alpha-melanocyte stimulating hormone (alpha-MSH), the endogenous MC1R agonist produced by keratinocytes after UV exposure. Every human who tans is transiently producing endogenous alpha-MSH. The melanoma risk associated with bremelanotide, if any, would need to be distinguished from the background signal generated by normal tanning physiology. This distinction has not been made experimentally [6].

Post-Marketing Surveillance and the FDA Registry

As a condition of approval, Palatin Technologies (subsequently AMAG Pharmaceuticals, now Cosette Pharmaceuticals) agreed to maintain an ongoing post-marketing safety registry. FDA Medication Guide and REMS-adjacent pharmacovigilance requirements specify that cases of new or changing melanocytic lesions should be reported through MedWatch [3].

What Post-Marketing Data Show So Far

FDA Adverse Event Reporting System (FAERS) data available through Q2 2024 list 14 reports of skin pigmentation changes coded under bremelanotide's NDA, with zero cases coded as melanoma or malignant melanoma. These FAERS reports are subject to voluntary reporting bias, underreporting, and confounding, so a negative signal does not eliminate risk. It does, however, suggest the signal has not emerged strongly enough to prompt spontaneous clinician reporting in the five years since approval.

HealthRX Pre-Prescribing Skin Assessment Protocol

Based on the mechanistic data, RECONNECT findings, and FDA label requirements, HealthRX clinicians use the following stepwise framework before initiating bremelanotide:

1. Personal oncologic history. Screen for any prior diagnosis of melanoma or non-melanoma skin cancer. Prior melanoma is a relative contraindication until the patient has been evaluated by a dermatologist who is aware of the intended therapy.
2. Family history. First-degree relatives with melanoma warrant dermatology consultation before the first prescription.
3. Phototype and MC1R phenotype proxies. Red or light blonde hair, blue or green eyes, and Fitzpatrick skin type I or II are phenotypic proxies for MC1R variant carrier status and increase background melanoma risk by approximately 2-fold [2].
4. Baseline full-body skin exam. Document existing nevi count, size, and any ABCDE-atypical features. Photograph lesions above 5 mm.
5. Patient education. Instruct patients to report new darkening of existing moles, new pigmented spots on the face or gingiva, or any lesion that bleeds without trauma.
6. Follow-up interval. Repeat skin documentation at 6 months for standard-risk patients and at 3 months for elevated-risk patients (Fitzpatrick I/II, family history, prior atypical nevi).

Focal Hyperpigmentation: Clinical Recognition

The hyperpigmentation pattern seen with bremelanotide is distinctive. It tends to appear on the face (particularly the forehead and periorbital areas), the gingiva, and the breasts. The distribution mirrors the locations of highest MC1R density outside of sun-exposed dorsal skin [4].

Differentiating from Melanoma

Focal bremelanotide-associated hyperpigmentation is typically:

• Uniformly tan to brown (not variegated)
• Flat (no papular or nodular component)
• Symmetrically bordered
• Slowly progressive over weeks to months, not days

Melanoma in situ can appear clinically similar. Any lesion with irregular borders, diameter above 6 mm, or color variation should be referred for dermoscopy and possible biopsy regardless of the clinical setting of bremelanotide use.

Management of Hyperpigmentation

There is no approved treatment to reverse bremelanotide-associated hyperpigmentation. Topical hydroquinone 4% has been used anecdotally in affected patients, with modest results. The primary intervention is drug discontinuation, followed by expectant monitoring. As noted above, lesions persist in roughly 50% of affected patients at six months post-discontinuation [4].

Cardiovascular Signal Versus Oncologic Signal: Prescribing Priority

Clinicians reviewing Vyleesi safety often spend more time on the transient blood pressure elevation (mean peak systolic increase of 6 mmHg, lasting approximately 12 hours post-injection) than on the cancer signal [4]. This is clinically appropriate: the cardiovascular signal is acute, reproducible, and the basis for the drug's strongest contraindication. The oncologic signal is theoretical, mechanistically plausible, and unconfirmed.

Both signals deserve attention. A patient with cardiovascular disease plus multiple atypical nevi and a first-degree relative with melanoma faces compounding precautions that may make bremelanotide a poor therapeutic choice compared to alternatives such as flibanserin (Addyi), which lacks a melanocortin mechanism entirely [8].

Special Populations: Elevated Melanoma Risk

BRCA Carriers and Melanoma Risk

BRCA1 and BRCA2 pathogenic variant carriers have a modestly elevated baseline melanoma risk (relative risk approximately 1.5 for BRCA2) [9]. Whether adding a MC1R agonist to this background risk is clinically meaningful is unknown. Given the absence of data, HealthRX recommends dermatology co-management in BRCA-positive patients before initiating bremelanotide.

Immunocompromised Patients

Organ transplant recipients and patients on immunosuppressive therapy have baseline melanoma incidence rates 2- to 8-fold above the general population due to impaired immune surveillance [10]. Bremelanotide has not been studied in this population, and the theoretical additive risk of melanocortin-driven melanocyte proliferation combined with impaired immune clearance of atypical cells is a reason to exercise caution. These patients are not explicitly excluded in the label, but no data support use in transplant recipients.

What Clinicians Should Tell Patients

Patients asking about cancer risk deserve a calibrated answer. The evidence supports these statements:

• No human clinical trial has recorded a case of cancer caused by bremelanotide.
• The drug changes skin pigmentation in about 1 in 100 users, and those changes can be permanent.
• The drug works on the same receptor involved in melanin production and, in some animal models, in benign melanocytic lesions at doses far above clinical use.
• A baseline skin check and awareness of new or changing spots are reasonable precautions, not alarmist.
• Patients with a personal or family history of melanoma should speak with a dermatologist before starting this medication.

The 2019 RECONNECT investigators concluded: "Focal hyperpigmentation was more common with bremelanotide than placebo and may be persistent; patients should be counseled about this risk before initiating therapy." [4] That guidance remains the standard of care.

Regulatory Outlook and Ongoing Evidence Gaps

The post-marketing registry has been collecting data since mid-2019. A five-year interim review by the FDA, expected around 2024 to 2025, may provide updated guidance on the melanoma precaution. If the registry generates more than 500 patient-years of exposure data with zero melanoma cases, the FDA may consider downgrading the language from a precaution to an informational note, as occurred with the MC1R agonist afamelanotide after its own accumulating post-marketing evidence.

The primary evidence gap is a prospective study using dermoscopy or total-body photography to quantify nevi changes in bremelanotide-treated versus untreated women over at least two years. No such study has been registered as of July 2025. Clinicians who identify pigment changes in treated patients should photograph and submit these via MedWatch (1-800-FDA-1088) to help build the post-marketing evidence base [3].